Cangrelor for treatment of coronary thrombosis. - Wikidata - awgldk - TriplyDB

Cangrelor for treatment of coronary thrombosis.

Cangrelor for treatment of coronary thrombosis.

http://www.wikidata.org/entity/Q36440860

about

Cardiac purinergic signalling in health and disease Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines New antithrombotic drugs.Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Antiplatelet therapy in acute coronary syndromes.Cangrelor for treatment of arterial thrombosis.Strategy for the treatment of clopidogrel low responsiveness in diabetes mellitus and stent implantation.Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects.

P2860

Q33165093-F2DB3485-8B4A-4F8B-864B-C6499BFFE552 Q33902628-CE6825A1-5BAF-4DCF-9C8F-53FC0D6278BF Q34771381-E1B11DF1-974A-4A9F-B206-16B4C36A43F6 Q35752611-DC82713D-3243-4CE1-8128-7C6B0D248B0B Q37530424-E20C49C2-665D-4D8A-8F53-54D71774CF8B Q37532491-27FBB68E-9D91-432B-A440-1328B48C41F9 Q37550156-536189DD-2D69-4DE9-9F43-AD3BCD33116C Q37798110-1CF6BD65-FCE5-4A2D-985D-D46C05607FDB Q38183489-6DFF4AA1-797B-4E4E-9AE0-A47F54E1ED18 Q42228752-59B6EEB4-210A-4988-9A9C-C752483B53AF Q42542451-0C8B3ACB-C95F-4E05-832F-B08392E983DD

P2860

Cangrelor for treatment of coronary thrombosis.

http://www.wikidata.org/entity/Q36440860

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Cangrelor for treatment of coronary thrombosis.

@ast

Cangrelor for treatment of coronary thrombosis.

@en

type

label

Cangrelor for treatment of coronary thrombosis.

@ast

Cangrelor for treatment of coronary thrombosis.

@en

prefLabel

Cangrelor for treatment of coronary thrombosis.

@ast

Cangrelor for treatment of coronary thrombosis.

@en

P1433

Q36440860-BB40D7D4-28FC-429A-BB24-740A9A79CDB3

P1476

Q36440860-16024C58-F7E2-4B63-83E1-081703685E8E

P2093

Q36440860-A89E783B-47DB-484D-BE55-C76EB544076F

Q36440860-BA8F2F83-13CE-4DBF-BFAC-FB87BCF6FDF3

P2860

Q36440860-076091EC-6CA2-4E42-8128-C954DDE7483F

Q36440860-10753D21-F372-45C6-B5E0-398386C518DE

Q36440860-4458D1B2-AD1D-4A91-B347-AA9724A6FE0E

Q36440860-510D8DA0-D1ED-4D76-BED9-B2C4738B0F86

Q36440860-6B3AD621-80A1-4F70-B374-F0D29C35B6CF

Q36440860-6BCDEA5B-38AE-4047-BAC0-80216FA4DA22

Q36440860-7AAD9332-5E72-4E79-9727-3870C50741E9

Q36440860-A426036E-F2AB-4974-9980-D1C88A98C656

Q36440860-B1195D19-330F-4729-9EE5-3875688572A9

Q36440860-CFE85263-593D-486C-A36A-35B6C5ECB07A

P304

Q36440860-D1A66488-4FA7-4429-98B4-92384AF0C139

P31

Q36440860-055B6133-75F5-4F72-816F-8B5B79BC97BB

P356

Q36440860-D5D2A6F5-1E1F-4B4B-8B85-9A0B3BFE0ACE

P407

Q36440860-1AD351B0-90F9-4625-8670-AFCD619496A1

P433

Q36440860-6F4C3702-F94C-48E1-BABA-5A02D7503CEF

P478

Q36440860-2EEACDD7-3891-4A0D-9E56-90E29FC0E6B1

P577

Q36440860-5E1E0B39-E24A-477D-8B97-DAF01525BC0E

P698

Q36440860-155F5283-4809-4EAB-91BF-A3B48961FA31

P921

Q36440860-848D58EE-169A-4A29-9A8D-61C388BBE57B

P356

P1433

Annals of Pharmacotherapy

P1476

Cangrelor for treatment of coronary thrombosis.

@en

P2093

Laura A Cudd

http://www.w3.org/2001/XMLSchema#string

Susan E Fugate

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials

The P2Y12 receptor as a therapeutic target in cardiovascular disease

Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

ADP receptors--targets for developing antithrombotic agents.

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.

A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis.

P304

925-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G120

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16595568

http://www.w3.org/2001/XMLSchema#string

P921